Market research
IMUX Immunic Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 225M
- P/E ratio
- Not available
- Analyst target
- 42.1818
- Dividend yield
- Not available
- Beta
- 1.4
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4525EP2001
- Market cap
- 225M
- P/E ratio
- Not available
- Analyst target
- 42.1818
- Dividend yield
- Not available
- Beta
- 1.4
About
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IMUX discussion.
5 years, 4 months ago
Immunic, Inc is currently in a long term downtrend where the price is trading 24.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Immunic, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 45.1% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 122.4% to $-14M since the same quarter in the previous year.
Based on the above factors, Immunic, Inc gets an overall score of 1/5.